Recruiting

Urinary Bladder Matrix

Sponsor:

Integra LifeSciences Corporation

Code:

NCT07805798

Conditions

Tissue Repair

Soft Tissue Reconstruction

Wound Management

Pressure Ulcer (PU)

Necrotizing Soft Tissue Infection

Eligibility Criteria

Sex: All

Age: 21+

Healthy Volunteers: Not accepted

Interventions

Urinary Bladder Matrix (UBM) Products

Study Details

Brief summary:

The purpose of this registry is to collect real-world information on patients treated with Urinary Bladder Matrix (UBM) products. The study will evaluate patient characteristics, treatment patterns, and clinical outcomes to better understand how UBM products are used in routine clinical practice and the outcomes experienced by patients over time.

Conditions

Tissue Repair

Soft Tissue Reconstruction

Wound Management

Pressure Ulcer (PU)

Necrotizing Soft Tissue Infection

Study ID

NCT07805798

Start date

Oct 23, 2026

Status verified date

Nov, 2026

Completion date

Dec 31, 2029

Anticipated

Primary completion date

Aug 31, 2029

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 21+

Healthy Volunteers: Not accepted

Inclusion Criteria

  • Adults aged ≥21 years at the time of initial urinary bladder matrix (UBM) product application.
  • Received or are receiving an eligible UBM product for treatment of a qualifying wound, including:

Pressure ulcer (Stage III/IV) Necrotizing soft tissue infection (NSTI) Fournier's gangrene Pilonidal cyst Open abdomen Hidradenitis suppurativa Acute or chronic lower extremity wound Surgical incisional wound (retrospective cohort only)

  • For retrospective participants, medical records must contain sufficient source documentation to support data abstraction, including wound characteristics, UBM treatment information, and post-treatment outcome data.
  • For prospective participants, written informed consent must be obtained prior to any registry-related data collection, and the participant must be expected to remain available for follow-up through approximately 12 months after the index UBM application.

Exclusion Criteria

  • Wound treated with a skin substitute prior to UBM treatment.
  • Wound not treated with a UBM product.
  • Full-thickness (third-degree) burn wound.
  • Participation in another interventional clinical trial that, in the opinion of the investigator, may affect wound-healing outcomes.
  • Known terminal condition, limited life expectancy, inadequate medical records, or any other circumstance that, in the opinion of the investigator, would preclude meaningful participation in the registry or collection of adequate outcome data.

Study Design

Enrollment

300 participants

Anticipated

Interventions and Outcome Measures

Arms

Retrospective Cohort

Patients with qualifying wounds previously treated with an eligible UBM product whose clinical data are collected through abstraction of existing medical records. No study-specific interventions, procedures, or follow-up visits are required. Participants are enrolled under an IRB-approved waiver of informed consent, where applicable.

Prospective Cohort

Patients receiving treatment with an eligible UBM product for a qualifying wound who provide informed consent and are followed through routine standard-of-care clinical visits. Clinical data are collected prospectively from the medical record without protocol-mandated interventions or visits.

Interventions

Urinary Bladder Matrix (UBM) Products

Commercially available UBM wound management products used as part of routine clinical practice. Treatment selection, application frequency, and wound management approach are determined by the treating clinician and are not dictated by the registry protocol.

Primary outcome measure

  • Proportion of Patients With Device-Related Adverse Events [ Time Frame: Up to 12 months following the initial UBM product application. ]

Central Contacts and Locations

Locations

HonorHealth Research Institute

Recruiting

Scottsdale, Arizona, United States, 85258

Contacts

Principal Investigator:

Gina Golden

The University of North Carolina at Chapel Hill

Recruiting

Chapel Hill, North Carolina, United States, 27599

Contacts

Principal Investigator:

Booker King

Atrium Health

Recruiting

Charlotte, North Carolina, United States, 28207

Contacts

Principal Investigator:

Laurence Kempton

More Information

Sponsor

Integra LifeSciences Corporation

Last update posted

Nov 20, 2026

Last verified

Nov, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-21. This information was provided to ClinicalTrials.gov by Integra LifeSciences Corporation on 2026-11-20. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.